How This Database Was Built
A 4-stage qualification funnel.
Only one group of people completed all four steps. That's the database you're licensing.
Condition-specific unbranded ad.
Category-level unbranded campaigns — mail-order Rx, supply delivery (CPAP, diabetic, pain), and Medicare / insurance coverage. Condition-specific only — no drug or brand. Served to a broad audience for each condition. 100% of campaign spend reaches this stage.
Through to landing page.
A smaller subset showed enough interest to click through to the condition-specific landing page. Typical CTR of 2–8%. Everyone here chose to learn more.
Self-selection event.
Arrived at the condition-specific supply, Rx, or coverage form. Unbranded. Specific. This person is interested — they're on a form asking about their condition, their supplies, their Rx history, or their insurance needs.
Completed form or called in. Confirmed their condition.
Stated their condition. Expressed Rx, supply, or coverage interest. Provided contact information. Gave explicit opt-in consent. Every record in the Summit database is a person who completed this final step — by submitting a form or picking up the phone — 15.3M+ condition-confirmed inquiries.
A pharma brand or health marketer licensing this database can run a CPM campaign against the post-conversion audience — the people who already proved intent — without building the funnel themselves. Ten-plus years of direct-response spend, tens of millions of impressions, and 15.3M+ condition-confirmed inquiries already did it.
Licensing Structures
Four ways to license or partner.
Full Exclusive License
Exclusive access to the entire dataset across all conditions and tiers. Maximum competitive moat. Premium licensing terms.
Category Exclusive
Exclusive rights within a specific therapeutic category or vertical (e.g. diabetes, sleep apnea) — others remain available to other partners.
Non-Exclusive License
Standard licensing of segments by condition, tier, and use case. Fastest path to activation. Multiple licensees may co-exist.
Partnership / Rev-Share
Strategic distribution model — partner enriches and resells through their channels; revenue splits between Summit and partner per agreed structure.
PHI never leaves Summit
De-identification and hashing happen in our environment before any handoff.
Hash-based matching
SHA-256 email and phone hashes resolve to anonymous tokens — never to people.
BAA available
Business Associate Agreement available for partners requesting added HIPAA cover.
How It Goes to Market
Activation, distribution & partnership models.
Summit's verified first-party records are activated through a privacy-safe pipeline. We strip PHI and hash identifiers before any data leaves our environment; partners enrich, match, and distribute through their channels. Buyers never see records — only segments.
De-identify & Hash
Strip all PHI. Hash email and phone with SHA-256. Attach condition tag & tier classification only.
Enrich & Match
Partner runs hashes through identity resolution (LiveRamp, Experian) and layers their consumer/clinical data on the resolved token.
Package & List
Enriched, fully de-identified segments are listed in clean rooms and data marketplaces — Snowflake, AWS, LiveRamp.
Activate & Share
Pharma brands, agencies, and DSPs license segments. Revenue flows back via licensing fee or rev-share structure.
Data Authenticity
The record behind every record.
"Every record represents a real person who responded to direct marketing campaigns and confirmed their condition. This data was licensed from partners who invested tens of millions in direct-response marketing spend — not purchased from brokers, not scraped, not modeled. First-party, deterministic, and verified through actual healthcare customer acquisition."
Direct Marketing Investment
Direct digital marketing investment over 10+ years. Every record originated from a real marketing interaction — not a data broker.
Self-Reported & Confirmed
Conditions are self-reported and confirmed — not modeled or inferred from behavioral proxies. Real people who confirmed they have the condition.
TCPA-Compliant Opt-In
Collected through TCPA-compliant opt-in landing pages. Independently reviewed methodology. Clean chain of custody.
Condition Coverage
Conditions across all four tiers.
Every segment below spans T1, T2, T3, and HCP — from confirmed Rx fulfillment back to first intent signal.
Diabetes
Confirmed diabetic patients across all tiers. Longitudinal supply history, prescriber linkage, and comorbidity data available. Primary condition in the Summit pipeline since 2016.
Sleep Apnea
Obstructive, central, and mixed sleep apnea patients. Segments by PAP device type (CPAP, BiPAP, APAP), compliance status, severity, and geography. Refill cadence available in T1.
Respiratory
Respiratory condition patients including CPAP and airway supply recipients. Overlapping population with sleep apnea. T1 supply records include device type and fulfillment history.
Incontinence
Confirmed incontinence supply patients across T1 and T2. Catheter and absorbent supply types available. Longitudinal fill records and prescriber linkage available in T1.
Chronic Pain
Confirmed chronic pain patients across T1, T2, and T3. rxConditions field confirms joint inflammation and pain management comorbidities across the full file.
Polypharmacy
5,839,361 polypharmacy intent records. 374,000 confirmed patients with 7+ active Rx. 179,000 with 10+ active Rx. 95,565 confirmed pharmacy handoffs. ~47% inbound click-to-call (premium intent) / ~53% form completions. Specialty pharmacy, PBM, adherence program, and drug plan activation. Sub-segment of the T3 Intent Panel.
Cardiac / AFib
433,128 confirmed cardiac patients from clinical billing records. 419,592 with hashed phone — identity-resolved and matchable across all Summit tiers. 58,681 confirmed AFib — primary target for anticoagulant brands. 763 cross-matched to T1 confirmed DME supply. 948 cross-matched to T2 qualified intake. Approximately 5,600–11,300 cross-matched to T3 self-reported diabetes intent — the GLP-1 cardiovascular DTC audience. 73,128 cardiologist and electrophysiologist NPIs. CPT + ICD-10 confirmed diagnosis — deterministic, not modeled prevalence.
Medicare Advantage Enrollment
982,915 unique Medicare Advantage patients (1,176,096 intent records). 130,440 confirmed Medicare Advantage intakes delivered. 127,828 dual-eligible (Medicare + Medicaid). 68,823 with 6Meds polypharmacy crossover. 99.5% inbound click-to-call. Condition-verified diabetic and OSA population — prime D-SNP, Part D, and GLP-1 Bridge activation audience. Medicare GLP-1 Bridge effective July 1, 2026 activates 359,869 confirmed T1+T2 diabetes patients. Sub-segment of the T3 Intent Panel.
GLP-1 / Obesity
19,470 unique GLP-1 patients · Summit-operated fulfillment · 50 US states · 98.9% phone-hash coverage. ~294K estimated GLP-1 indicated patients from confirmed diabetes population (NIH/ADA prevalence model — always disclosed as probabilistic). 68.4% Tirzepatide, 28.8% Semaglutide. Full Intent Panel of ~15.3M records activatable for new patient acquisition. Medicare GLP-1 Bridge effective July 1, 2026 — $50/month Wegovy, Zepbound, and Foundayo for Medicare patients.
The Comorbidity Multiplier
This is not a single-condition dataset.
The primary conditions are diabetes and sleep apnea — gateway conditions with massive comorbidity profiles. A confirmed diabetic patient is simultaneously relevant to cardiology, nephrology, ophthalmology, neurology, mental health, weight management, and more.
Diabetes Comorbidities
- Hypertension (>50% of diabetics)
- Dyslipidemia
- Cardiovascular disease
- Obesity & metabolic strain
- Diabetic nephropathy
- Diabetic neuropathy
- Diabetic retinopathy
- Peripheral arterial disease
- Stroke
- Depression & mental health
- Erectile dysfunction
- Skin & dental problems
Sleep Apnea Comorbidities
- Hypertension
- Cardiovascular disease & stroke
- Type 2 diabetes
- Obesity
- Metabolic syndrome
- Cognitive impairment
- Depression & anxiety
- GERD
- Atrial fibrillation
- Pulmonary hypertension
- NAFLD
- Chronic fatigue
Therapeutic categories reachable from this dataset
What this means for buyers — One patient record is relevant to multiple therapeutic categories simultaneously. 15.3M+ condition-confirmed inquiries across four data tiers = a dataset relevant to nearly every major therapeutic category.
Getting Started
Three steps to a custom proposal.
Initial Conversation
Tell us your therapeutic area, target audience, and use case. 30 minutes is enough to understand what's possible.
Define Scope & Use Case
We map your objectives to available segments — condition, stage, geography, licensing structure.
Custom Proposal
Receive a tailored data proposal with segment specs, record counts, delivery format, and licensing terms.
Who This Is For
Find your platform type.
Six buyer categories. Every one of them gets something different from Summit. Find yours — then let's talk.
Healthcare Advertising DSP
Run condition-specific DTC campaigns against the only post-conversion, first-party patient audience in healthcare. T3's 15.3M+ confirmed intent records are the highest-quality patient segment available at CPM — not look-alikes, not modeled proxies.
Identity Graph & Data Onboarding
74.5% email match rate + 100% SHA-256 hashed phone on every T3 record. T3 resolves to an average of 3.2 devices per patient — cross-device reach at scale without PII leaving our environment.
Healthcare Data Clean Room
Already de-identified and SHA-256 hashed — zero friction for clean room ingestion. Token-link for script lift attribution, CRM suppression, and RWD enrichment. Compatible with Snowflake, AWS, and LiveRamp environments out of the box.
Healthcare Analytics & Patient Journey
Summit captures diagnosed patients at the point of in-market intent — when they are actively shopping for a new supplier, delivery channel, or coverage plan, but before the next prescription, refill, or enrollment event the claims data will eventually show. T3 is the upstream demand signal that claims data captures only after the script is filled.
Pharma Brand & Direct
Identity match + closed-loop script attribution. Reach confirmed condition patients at scale, then prove ROI via prescription attribution back to the original T3 or T1 record. The only healthcare audience where the conversion chain is documented end-to-end.
Clinical Research Organization (CRO)
15.3M T3 records with condition, age range, state, and comorbidity data — the fastest path to trial-eligible patient lists. Filter by condition, geography, age, and comorbidity profile. Compliant, de-identified, and activation-ready for site engagement outreach.